The Food and Drug Adminitration in the US has granted priority review status to a New Drug Application for a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) for the treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC).

The application is based on data from the phase 3, randomised, open-label CheckMate-214 trial, which was halted early because of a recommendation from an independent Data Monitoring Committee after a planned interim analysis of overall survival (OS).

Read more in Clinical Oncology News here